Globus Medical Reports Q3 2026 Results with Downward Revenue Guidance Revision
Globus Medical (GMED) reported third-quarter net sales of $763.7 million, a slight decrease of 0.7% year-over-year. The decline was primarily driven by a significant 25.7% drop in revenue from the Nevro segment and product launch delays within the U.S. Spine business. Consequently, the company adjusted its full-year 2026 revenue guidance downward to $3.09 billion from the previous range of $3.18 billion to $3.22 billion. Despite top-line challenges, the company demonstrated strong profitability and cash flow metrics. Non-GAAP EPS rose 4.4% to $1.23, and adjusted gross profit margins improved to 69.5%. The company also achieved a record quarterly free cash flow of $224.8 million. Growth in Enabling Technologies (up 24%) and Trauma revenue (up 19%) provided some offset to the softness seen in international markets and the Nevro business.
Topics: Free Cash Flow Net Sales Non-GAAP EPS Revenue Growth Segment Performance
Read the full article at Motley Fool
Part of the story Health Catalyst Reports Q3 2026 Results Exceeding Revenue and EBITDA Guidance (7 articles)